---

---

published : Today    crawled time : 07:00   

save search

---

ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Published: 2024-04-23 (Crawled : 07:00) - biospace.com/
IBRX | $4.94 -6.26% -6.57% 3.9M |

Manufacturing

| Email alert Add to watchlist
il-15 anktiva fda agonist approval bladder cancer for

---

Together Selects nCino to Revolutionise its Lending Business
Published: 2024-04-23 (Crawled : 07:00) - globenewswire.com
NCNO | $29.64 0.78% 0.78% 990K |

Technology Services

| Email alert Add to watchlist
business

---

SFL - Acquisition of two LNG dual-fuel chemical carriers in combination with long term employment
Published: 2024-04-23 (Crawled : 07:00) - globenewswire.com
SFL | $12.81 0.79% 0.0% 410K |

Transportation

| Email alert Add to watchlist
acquisition

---

Teledyne e2v and Airy3D collaboration delivers more affordable 3D vision solutions
Published: 2024-04-23 (Crawled : 07:00) - globenewswire.com
TDY | $404.08 0.68% 0.0% 240K |

Electronic Technology

| Email alert Add to watchlist
solutions vision collaboration

---

Zscaler Research Finds 60% Increase in AI-Driven Phishing Attacks
Published: 2024-04-23 (Crawled : 07:00) - globenewswire.com
ZS | $170.97 1.04% 1.04% 1.1M |

Technology Services

| Email alert Add to watchlist
research

---

HighByte Announces Series A Raise to Accelerate Growth in Industrial DataOps Market
Published: 2024-04-23 (Crawled : 07:00) - prnewswire.com
IT | $443.06 0.61% 0.0% 390K |

Commercial Services

| Email alert Add to watchlist
series growth market

---

Banking heavyweight Markus Sauerland, former CEO of Nomura Financial Products Europe GmbH, joins NowCM as COO and Co-CEO
Published: 2024-04-23 (Crawled : 07:00) - prnewswire.com
XYF | News | $3.9 3.18% 0.0% 6K |

Finance

| Email alert Add to watchlist
ARVL | News | $0.49 0.37% 2.5M |

Manufacturing

| Email alert Add to watchlist
europe ceo financial

---

HanxBio announces the publication of a research paper in Scientific Reports on preclinical evaluation of Narazaciclib for the treatment of acute myeloid leukemia (AML)
Published: 2024-04-23 (Crawled : 07:00) - prnewswire.com
ONTX | $0.9953 -5.61% 1.3M |

Health Technology

| Email alert Add to watchlist
publication treatment research preclinical for leukemia

---

Gainers vs Losers

73%

27%

Top 10 Gainers

MTTR | News M | $4.8 175.86% 63.6% 71M |

AGBA | $2.5 100.0% 56.6% 200M |

Finance

MLEC | $2.47 76.43% 42.62% 78M |

n/a

NUWE | $0.334 29.96% 40.99% 2.5M |

Manufacturing

EDBL | News | $6.26 66.49% 40.13% 16M |

ATGL | $2.86 46.25% 32.8% 180K |

VIVK | $1.43 33.65% 27.7% 530K |

Professional, Scientific, and T...

MNTS | $0.5 35.69% 26.3% 4.7M |

SDIG A | $3.64 35.32% 26.0% 990K |

PROK | $2.72 33.33% 24.58% 2.6M |

---

Your saved searches

---